AnaptysBio(ANAB) - 2024 Q3 - Quarterly Results

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update • Phase 1 trial initiated in healthy volunteers for ANB033, our anti-CD122 antagonist • Reiterating cash runway through year-end 2026 SAN DIEGO, Nov. 5, 2024 — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended Sept. 30, 2024 and provided a business update. "We remain confident in the po ...